65
Participants
Start Date
July 19, 2018
Primary Completion Date
March 18, 2022
Study Completion Date
March 18, 2022
XEN45
XEN45 unilaterally implanted in the study eye
Marsden Eye Specialists Parramatta /ID# 232761, Paramatta
Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765, Vermont South
Taipei Veterans General Hospital /ID# 232948, Taipei City
Buddhist Tzu Chi General Hospital /ID# 232664, Hualien City
Nuh Medical Centre /ID# 232905, Singapore
Tan Tock Seng Hospital /ID# 233014, Singapore
Melbourne Eye Specialists /ID# 232767, Fitzroy
Institut de loeil des Laurentides /ID# 232780, Boisbriand
Ophthalmology Clinic Bellevue /ID# 232782, Montreal
Prism Eye Institute /ID# 232917, Mississauga
Seoul National University Hospital /ID# 233099, Seoul
Royal Surrey County Hospital /ID# 233028, Guildford
Manchester University NHS Foundation Trust /ID# 232808, Manchester
Queen Victoria Hospital /ID# 232812, East Grinstead
East Suffolk and North Essex NHS Foundation Trust /ID# 232804, Colchester
NHS Lothian /ID# 233052, Edinburgh
Lead Sponsor
Allergan
INDUSTRY